Cure My Disease

Don't miss your cure!

 Log in / Sign up

New HIV prevention drug faces drug interaction test

NCT ID NCT07600775

Knowledge-focused Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This early-stage study looks at how a common tuberculosis drug, rifampin, affects levels of a new HIV prevention medicine called MK-8527. Fourteen adults with latent TB (no active symptoms) will take MK-8527 with and without rifampin. The goal is to see if the two drugs can be used together safely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MK-8527 and rifampin
What this could lead to
If successful, this study could help determine if MK-8527 can be safely used with rifampin, potentially expanding HIV prevention options for people with latent TB.
What could go wrong
This is a very early, small Phase 1 trial with only 14 participants. It focuses on drug levels, not effectiveness or safety, and may not predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 14 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has a diagnosis of untreated latent tuberculosis infection (LTBI) * Has no symptoms of active tuberculosis (TB) * Has never received treatment for TB or LTBI * Other than having LTBI, is in good health Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a diagnosis of LTBI made in the context of an outbreak/contact-tracing investigation * Has a current or anticipated immunocompromised state * Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases * Has a history of cancer (malignancy) * Has a history of active TB * Has positive test results for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV pre-exposure prophylaxis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS latent tuberculosis infection HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV pre-exposure prophylaxis Human immunodeficiency virus (HIV)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.